Ceribell Announces New Critical Care Medicine Publication Reinforcing Link Between Seizure Burden Measured by Clarity AI Algorithm and Neurological Outcomes

Rhea-AI Summary

Ceribell (Nasdaq: CBLL) reported a new Critical Care Medicine publication linking its Clarity AI seizure-burden metric with neurological outcomes at discharge. The multicenter study of 359 adults across three academic hospitals found higher AI-detected seizure burden was associated with greater odds of severe disability or death.

Patients with peak 5-minute seizure burden ≥90% were 3.4 times more likely to have death or severe disability versus 0% burden, and each additional hour of Clarity-assessed seizure nearly doubled this risk (adjusted odds ratio 1.98). The paper is Open Access.

Positive

• 359-patient multicenter study links AI seizure burden to discharge outcomes
• Peak 5-minute seizure burden ≥90% shows 3.4x higher odds of death or severe disability
• Each extra hour of AI-detected seizure burden shows 1.98x higher adjusted odds of severe disability or death
• Study reinforces clinical decision support role of Ceribell’s Clarity AI in ICU and ED settings

Negative

• None.

News Market Reaction – CBLL

-0.60%

-0.60% Session close to close

In the Jun 8 session, CBLL declined 0.60%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement underscores further validation of Ceribell’s Clarity AI algorithm, showing that se...

Analysis

This announcement underscores further validation of Ceribell’s Clarity AI algorithm, showing that seizure burden measured on point-of-care EEG correlates with disability and death at discharge in 359 adults. It reinforces the system’s role in ICU and ED decision-making rather than changing near-term financial guidance. Investors may track how such peer‑reviewed data support broader clinical adoption, reimbursement traction, and integration alongside conventional nearly 24/7 EEG coverage across major academic centers.

Key Figures

Sample size: 359 adult patients Study sites: 3 academic centers Seizure burden threshold: ≥90% peak 5-minute burden +5 more

8 metrics

Sample size 359 adult patients Critical Care Medicine AI seizure burden study across three academic sites

Study sites 3 academic centers Yale, Massachusetts General Hospital, University of New Mexico

Seizure burden threshold ≥90% peak 5-minute burden Patients vs. 0% seizure burden comparator group

Risk of death/disability 3.4x higher odds Patients with ≥90% 5-minute seizure burden vs. 0% burden at discharge

mRS disability cutoff mRS ≥4 at discharge Definition of severe disability or death endpoint in study

Ongoing seizure risk Odds ratio 1.98 Each additional hour of Clarity-assessed seizure activity in EEG

Conventional EEG availability Nearly 24/7 Standard EEG coverage at participating academic centers

Publication year 2026 Critical Care Medicine advance online publication of Clarity AI study

Previous AI Reports

1 past event · Latest: Apr 30 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 30	AI compliance milestone	Positive	-1.6%	FedRAMP High authorization for AI-powered point-of-care EEG in federal systems.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Prior AI-related news saw a modest negative reaction despite clearly positive operational impact.

Recent Company History

Over the past year, Ceribell’s AI-related communications have emphasized expansion and validation of its point-of-care EEG platform. A key event on Apr 30, 2025 was FedRAMP High authorization for its AI-powered system, enabling broader deployment across federal healthcare facilities. Despite the strategic importance, the stock moved about -1.65%. Today’s AI outcomes publication similarly reinforces clinical and decision-support value rather than near-term financial changes.

Key Terms

point-of-care eeg, poc eeg, intensive care unit, emergency department, +4 more

8 terms

point-of-care eeg medical

"support Ceribell’s leadership in AI-powered Point-of-Care EEG (POC EEG), addressing a"

A point-of-care EEG is a compact, often portable device that records the brain’s electrical activity at the bedside or in outpatient settings, providing quick readings without sending patients to a specialized lab. For investors, it matters because faster, easier brain monitoring can speed diagnosis and treatment, cut hospital costs, and open broader markets for neurodiagnostic tools much like how portable heart monitors expanded cardiac care.

poc eeg medical

"support Ceribell’s leadership in AI-powered Point-of-Care EEG (POC EEG), addressing a"

Point-of-care EEG is a compact system that records brain electrical activity at or near the patient’s bedside, similar to how a portable EKG captures heart signals. For investors, it matters because faster, easier brain monitoring can shorten hospital stays, speed diagnosis, broaden use outside specialized units, and create new revenue opportunities for medical-device makers and health systems by lowering cost and time barriers to neurological care.

intensive care unit medical

"neurodiagnostics in the Emergency Department (ED) and Intensive Care Unit (ICU). Key"

An intensive care unit (ICU) is a hospital ward that provides round‑the‑clock monitoring and life‑support for patients with severe, potentially life‑threatening illness or injury. For investors, ICU capacity, staffing and outcomes are key indicators of a health provider’s operational strain and revenue mix—similar to how a restaurant’s kitchen size and staff determine how many customers it can serve during peak hours and how well it performs financially.

emergency department medical

"neurodiagnostics in the Emergency Department (ED) and Intensive Care Unit (ICU). Key"

A hospital’s emergency department is the 24/7 clinical unit that evaluates and treats people with urgent or life‑threatening conditions, acting like the hospital’s front door for immediate care. For investors, its volume and performance signal demand for healthcare services, affect hospital revenue and cost patterns, and influence regulatory and reimbursement risks—similar to how customer foot traffic informs the health of a retail business.

modified rankin scale medical

"death or severe disability as measured by a modified Rankin Scale (mRS) score equal"

A clinical tool that rates a person’s level of disability and dependence following a neurological event, most commonly stroke, on a simple scale from no symptoms to severe disability or death. Think of it as a one-number summary of how independently a patient can live after treatment—an important outcome measure because improvements on this scale often drive whether therapies are seen as effective by regulators, doctors and payers, and therefore influence a drug’s or device’s commercial prospects.

odds ratio medical

"Each additional hour of Clarity-assessed seizure in the EEG recording is associated with nearly a two-fold increase in risk of severe disability or death (adjusted odds ratio = 1.98)."

The odds ratio compares how likely an outcome is in one group versus another by dividing the odds of the event in the first group by the odds in the second. Think of it like comparing the odds of a coin landing heads in two different scenarios; a number above 1 means the event is more likely in the first group, below 1 means it is less likely. Investors use it to quantify how strongly a treatment, risk factor, or policy changes the chance of an outcome, which helps assess clinical trial results, regulatory risk, and potential impact on a company’s prospects.

biomarkers medical

"algorithm is detecting biomarkers of a disease state that are clinically relevant,"

Biomarkers are measurable indicators found in the body, such as substances in blood or tissues, that reveal information about health or disease. For investors, they can signal how well a medical treatment is working or whether a disease is developing, helping to assess the potential success or risks of healthcare companies or innovations. Think of biomarkers as biological signals that provide clues about a person’s health status.

open access technical

"The paper is available via Open Access on the Critical Care Medicine journal website."

Open access means that information or resources are available for anyone to view, use, or share without restrictions or costs. For investors, it matters because open access to data or research can provide transparent, timely insights that help inform better decisions and foster trust in the information being used. It’s like having free, unrestricted access to a public library rather than needing a special pass to enter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Study published in leading critical care journal shows that higher AI-detected seizure burden is associated with increased odds of disability, further demonstrating the utility of the Ceribell System as a clinical decision-making tool

SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that a new research paper entitled "Point-of-Care EEG Artificial Intelligence Measure of Seizure Burden Associates with Clinical Outcome at Discharge" was published in Critical Care Medicine (CCM),¹ the official, peer-reviewed scientific journal of the Society of Critical Care Medicine (SCCM).

The landmark study provides evidence that Ceribell’s Clarity^® artificial intelligence (AI) algorithm, specifically its measure of seizure burden, is correlated with a patient's functional outcomes at discharge. The findings further support Ceribell’s leadership in AI-powered Point-of-Care EEG (POC EEG), addressing a critical unmet need for rapid, actionable neurodiagnostics in the Emergency Department (ED) and Intensive Care Unit (ICU).

Key Research Findings:

The study analyzed data from 359 adult patients across three academic sites—Yale School of Medicine, Massachusetts General Hospital, and The University of New Mexico School of Medicine—where both Ceribell POC EEG and nearly 24/7 conventional EEG were available. Building upon the foundational SAFER-EEG (Seizure Assessment and Forecasting With Efficient Rapid-EEG) study, originally published in the peer-reviewed journal Neurology (July 2024),² the new analysis reveals:

• AI Measure of Seizure Burden Linked to Outcomes: Higher seizure burden detected by Ceribell’s Clarity algorithm was associated with increased severe disability and poorer functional outcomes at the time of discharge. Compared to patients with 0% seizure burden, those with a peak 5-minute seizure burden greater than or equal to 90% at any point during EEG monitoring were 3.4 times more likely to experience death or severe disability as measured by a modified Rankin Scale (mRS) score equal to or higher than four, at discharge.
• Time is Brain: Risk escalates with ongoing seizure activity. Each additional hour of Clarity-assessed seizure in the EEG recording is associated with nearly a two-fold increase in risk of severe disability or death (adjusted odds ratio = 1.98).
• Clinical Utility: Clarity is the first validated bedside tool to demonstrate a strong “dose-response” relationship between AI-estimated seizure burden and functional outcomes of severe disability or death, even after adjusting for multiple clinical covariates. Prompt recognition and management of seizure burden may be critical to improving outcomes in acute care.
  

"I am proud of this collaboration between the SAFER-EEG clinical study investigators and Ceribell’s clinical team," said Josef Parvizi, M.D., Ph.D., co-founder, board member and Chief Medical Adviser of Ceribell, and lead author of the paper. "This research confirms that Ceribell’s Clarity AI algorithm is detecting biomarkers of a disease state that are clinically relevant, providing a window into the patient's prognosis. Intervening faster to reduce seizure burden, as measured by Clarity, may potentially alter the trajectory of a patient's recovery."

"For the first time, physicians can directly and continuously monitor seizure burden—a key metric relevant to patient outcomes that was previously inaccessible in real time. This represents a fundamental shift from indirect or delayed and sporadic assessment toward continuous brain monitoring that leads to informed decision-making at the bedside,” said Jane Chao, Ph.D., co-founder and CEO of Ceribell. "At Ceribell, we strive to deliver real-time insights into the brain to empower medical teams to quickly identify and prioritize the care of critically ill patients in the ICU and ED."

The paper is available via Open Access on the Critical Care Medicine journal website.

References

1. Parvizi, J., et al. (2026). Point-of-Care Artificial Intelligence Measure of Seizure Burden Associates With Clinical Outcome at Discharge. Crit Care Med. Advance online publication.
2. Kalkach-Aparicio M, et al. (2024). Seizure assessment and forecasting with efficient rapid-EEG: a retrospective multicenter comparative effectiveness study. Neurology. 103(2):e209621.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other statements that are not statements of historical fact. Forward-looking statements can be identified by the use of words such as “will,” “may,” “could,” “likely,” “ongoing,” “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe,” “assume,” “target,” “forecast,” “guidance,” “goal,” “objective,” “aim,” “seek,” “potential,” “hope,” and other words of similar meaning. These statements are based on management’s current expectations and assumptions as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from those described. Such risks and uncertainties, including but not limited to those related to regulatory approvals, clinical use and adoption, clinical outcomes, market acceptance, competition, and other factors, are described under the “Risk Factors” sections of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other reports filed with the U.S. Securities and Exchange Commission (“SEC”). These filings are available on the SEC’s website at https://sec.gov/ and on Ceribell’s website at https://investors.ceribell.com/. Ceribell undertakes no obligation to update any forward-looking statements as a result of new information, future events, or otherwise, except as required by applicable law.

About CeriBell, Inc.

Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit http://www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston or Caylene Parrish
Gilmartin Group
Investors@ceribell.com

Media Contact
Brian Price
Press@ceribell.com

FAQ

What did Ceribell (Nasdaq: CBLL) announce on June 8, 2026 about its Clarity AI algorithm?

Ceribell announced a Critical Care Medicine publication showing its Clarity AI seizure-burden measure is associated with neurological outcomes at discharge. According to Ceribell, higher AI-detected seizure burden correlated with greater odds of severe disability or death in critically ill adults.

How is seizure burden measured by Ceribell’s Clarity AI linked to outcomes in the new CBLL study?

The study found higher Clarity-measured seizure burden was associated with worse functional outcomes at discharge. According to Ceribell, patients with peak 5-minute seizure burden ≥90% were 3.4 times more likely to experience death or severe disability versus those with 0% seizure burden.

What patient population and sites were included in the Ceribell Clarity AI seizure-burden study (CBLL)?

The analysis included 359 adult patients at three academic centers with both Ceribell point-of-care EEG and near-continuous conventional EEG. According to Ceribell, sites were Yale School of Medicine, Massachusetts General Hospital, and The University of New Mexico School of Medicine.

What does the adjusted odds ratio of 1.98 mean in Ceribell’s new Clarity AI publication?

The study reported that each additional hour of Clarity-assessed seizure activity nearly doubled the odds of severe disability or death. According to Ceribell, the adjusted odds ratio of 1.98 reflects this time-dependent increase in risk after accounting for clinical covariates.

Why is Ceribell’s Clarity AI seizure-burden tool important for ICU and ED decision-making?

Clarity enables continuous, bedside monitoring of seizure burden, a metric tied to outcomes in this study. According to Ceribell, real-time AI insights can help clinicians recognize and manage seizure burden more promptly in the ICU and Emergency Department, potentially influencing patient trajectories.

Where can investors and clinicians access the new Critical Care Medicine paper on Ceribell’s Clarity AI (CBLL)?

The research article on Clarity’s seizure-burden measure and discharge outcomes is available via Open Access. According to Ceribell, the paper can be read on the Critical Care Medicine journal website, which hosts the official publication for the Society of Critical Care Medicine.